COVID-19 Global Treatment Initiatives

A Leading Edge COVID-19 Response

As a drug re-purposing company, we investigate approved drugs with established safety histories for new disease applications, moving them efficiently and safely into new human trials, developing new formulations, and seeking new regulatory approvals in global markets.

Our program specifically investigates compounds that have never been approved in the U.S. or Europe, and we have protected our lead compounds with both method of use and new composition of matter patents for their derivatives and analogues.

We are moving aggressively to expand the investigation of our lead repurposed drug compound Ifenprodil as a new therapeutic treatment for COVID-19, in addition to acute lung injury (ALI). Please click here to view a short clip on Algernon’s Pre-IND Application with the U.S. FDA.

The below presentation summarizes our history with Ifenprodil, our confidence in its potential for use in immediate phase 2 clinical trials for the treatment of COVID-19, and the steps we have been taking towards achieving this.

Christopher J. Moreau
Chief Executive Officer

Mark Williams, PhD, MBA
Chief Science Officer

Algernon’s COVID-19 Research and Response

Algernon’s Ifenprodil Background

click here to read more

Independent Ifenprodil Studies

click here to read more

Confidence in a New COVID-19 Focus

click here to read more

Algernon’s COVID-19 Response

click here to read more

Additional NP-120 (Ifenprodil) and Media Information

More data on NP-120 (Ifenprodil)

click here to read more

Digital Media Articles and Video Interviews

click here to read more

News and Investor Resources

click here to read more

Additional Global COVID-19 Media

(coming soon)
Share via
Copy link
Powered by Social Snap